Colistimethate sodium | CAS# 8068-28-8 | antibiotic

MedKoo Cat#: 413233 | Name: Colistimethate sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Colistimethate sodium is an antibiotic used to treat certain bacterial infections. It works by stopping the growth of bacteria

Chemical Structure

Colistimethate sodium

CAS#8068-28-8

Theoretical Analysis

MedKoo Cat#: 413233

Name: Colistimethate sodium

CAS#: 8068-28-8

Chemical Formula: C58H105N16Na5O28S5

Exact Mass:

Molecular Weight: 1749.81

Elemental Analysis: C, 39.81; H, 6.05; N, 12.81; Na, 6.57; O, 25.60; S, 9.16

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Colistimethate sodium; W1929; W-1929; W 1929

IUPAC/Chemical Name

sodium 8-(1-hydroxyethyl)-5-((3-(1-hydroxyethyl)-12,15-diisobutyl-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris(2-((sulfonatomethyl)amino)ethyl)-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl)carbamoyl)-11-(6-methyloctanamido)-7,10-dioxo-2,6,9,14-tetraazapentadecane-1,15-disulfonate

InChi Key

IQWHCHZFYPIVRV-UHFFFAOYSA-I

InChi Code

InChI=1S/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5

SMILES Code

CCC(CCCCC(NC(C(NC(C(NC(C(NC1CCNC(C(C(O)C)NC(C(NC(C(NC(C(NC(C(NC(C(NC1=O)CCNCS(=O)([O-])=O)=O)CC(C)C)=O)CC(C)C)=O)CCNCS(=O)([O-])=O)=O)CCNCS(=O)([O-])=O)=O)=O)=O)CCNCS(=O)([O-])=O)=O)C(O)C)=O)CCNCS(=O)([O-])=O)=O)C.[Na+].[Na+].[Na+].[Na+].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,749.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Conole D, Keating GM. Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Drugs. 2014 Mar;74(3):377-87. doi: 10.1007/s40265-014-0181-0. PMID: 24510624. 2: Zavascki AP, Nation RL. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B? Antimicrob Agents Chemother. 2017 Feb 23;61(3):e02319-16. doi: 10.1128/AAC.02319-16. PMID: 27993859; PMCID: PMC5328560. 3: Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C, Cantrell A. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model. Health Technol Assess. 2013 Dec;17(56):v-xvii, 1-181. doi: 10.3310/hta17560. PMID: 24290164; PMCID: PMC4781138. 4: Bialvaei AZ, Samadi Kafil H. Colistin, mechanisms and prevalence of resistance. Curr Med Res Opin. 2015 Apr;31(4):707-21. doi: 10.1185/03007995.2015.1018989. Epub 2015 Mar 19. PMID: 25697677. 5: Pampa-Saico S, Pintado V, Muriel A, Caravaca-Fontan F, Yerovi-León E, Rojo- Sanchis A, Del Rey JM, Teresa Tenorio M, Liaño F. Colistimethate sodium and acute kidney injury: Incidence, risk factors, outcome and prognosis of renal function. Nefrologia. 2020 Nov-Dec;40(6):647-654. English, Spanish. doi: 10.1016/j.nefro.2020.04.007. Epub 2020 May 28. PMID: 32473742. 6: Benítez-Cano A, de Antonio-Cuscó M, Luque S, Sorlí L, Carazo J, Ramos I, Bermejo S, Campillo N, Horcajada JP, Samsó E, Grau S. Systemic pharmacokinetics and safety of high doses of nebulized colistimethate sodium in critically ill patients with hospital-acquired and ventilator-associated pneumonia. J Antimicrob Chemother. 2019 Nov 1;74(11):3268-3273. doi: 10.1093/jac/dkz356. PMID: 31495877. 7: Koerner-Rettberg C, Ballmann M. Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy. Core Evid. 2014 Sep 19;9:99-112. doi: 10.2147/CE.S64980. PMID: 25278817; PMCID: PMC4178503. 8: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Colistimethate. 2018 Oct 31. PMID: 30000388. 9: Kaplan S, Patino O, Rainville C, Madison T. Assessment of colistimethate sodium (COLOBREATHE) risk minimization measures implemented in the European Union: A cross-sectional study. Pharmacoepidemiol Drug Saf. 2020 Feb;29(2):219-223. doi: 10.1002/pds.4940. Epub 2019 Dec 9. PMID: 32914920. 10: Murali S, Pillai AV, Ramachandran R. Efficacy of colistimethate sodium as local application in necrotising fasciitis. BMJ Case Rep. 2019 Nov 26;12(11):e232354. doi: 10.1136/bcr-2019-232354. PMID: 31776156; PMCID: PMC6887469.